Navigation Links
Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver
Date:10/13/2010

her the use of ELAD in this setting can prevent continued deterioration of liver function, called progression, and thus improve survival. The trial design uses a well-established measure of liver function called the MELD score to define the status of liver function. Treatment with ELAD, along with standard of care, is compared with standard of care alone.  The time to either death or deterioration of liver function by a pre-specified amount is measured. It is postulated that the use of ELAD may extend the time to progression and improve survival in this rapidly progressing patient population.

ELAD is a biologic liver support system using a proprietary line of allogeneic human liver cells refined by several leading cell experts.  The cells are stable, immortal, can be grown in unlimited quantities and retain their hepatocyte (liver cell) characteristics.  About one pound of cells is used for each treatment. The cells are grown in specially designed cartridges at VTI's cell culture facility and used to treat the patient for up to ten days.

About Vital Therapies, Inc.

Vital Therapies, Inc. (VTI) is based in San Diego, California, with a wholly owned subsidiary in Beijing, China.  VTI is developing the first human liver cell-based Extracorporeal Liver Assist System (ELAD).  ELAD could provide support for patients with severe liver failure by processing toxins and also synthesizing proteins and metabolites that are key products of normal human liver function. ELAD is in investigational clinical trials and VTI completed a pivotal trial and filed for market approval in China in September 2007.  For additional information visit www.vitaltherapies.com or contact Terry Winters, PhD, CEO, Vital Therapies at +1 858 673 6840.

ELAD is a trademark of Vital Therapies, Inc.


'/>"/>
SOURCE Vital Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
3. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
4. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
5. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
6. Comfort Medical Supply, LLC Ranks No. 461 on the 2010 Inc. 500 with Three-Year Sales Growth of 649%
7. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
8. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
11. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Novavax, Inc. (Nasdaq: NVAX ), a clinical-stage vaccine ... Novavax, will be presenting at the ROTH 23rd Annual OC ... local time at The Ritz Carlton, Laguna Niguel, CA.  A ... via the Company website at www.novavax.com under Investors/Events, ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... the extracellular matrix for the endocrinology, ... financial results for the fourth quarter and year ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "I am energized and ...
Cached Medicine Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 6
(Date:4/18/2014)... online in The Gerontologist reports ... associated with a decrease in anxiety about death and ... over their lives. In particular, listening to gospel music ... and an increase in sense of control. , These ... men, and individuals of both low- and high-socioeconomic status. ...
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... ROCKVILLE, Md., March 5 Americans and nonprofit organizations ... of these circumstances, The Larry King Cardiac Foundation (LKCF), ... for individuals with no health insurance, has announced that ... 2009.In lieu of its annual black tie gala held ...
... happens may lead to ways around it, researchers say, ... standard treatment for brain cancer, may boost the aggressiveness ... a new study suggests. , The research team, from ... identified cells in brain tumors called gliomas that have ...
... response to a recent report by the National Council ... U.S. population is exposed to seven times more radiation ... Americans to consider the proven benefits of such imaging. ... technologists support the use of diagnostic imaging when deemed ...
... WASHINGTON, March 5 Stephen J. Ubl, president and CEO ... the Medical Device Safety Act to be introduced today in Congress. If ... , Chill innovation and ... Dramatically alter the regulatory environment for certain medical devices, ...
... March 5 Stephen J. Ubl, president ... released the following statement today regarding the re-introduction of ... not in any way improve patient safety. It will, ... a chilling effect on medical innovation, create more lawsuits ...
... Dialysis Corporation of America (Nasdaq: DCAI ) announced its financial ... , , ... dialysis center acquired December 31, 2008. , ... $23.7 million compared to $20.0 million for the same period last year, ...
Cached Medicine News:Health News:The Larry King Cardiac Foundation Brings its Annual Gala to Homes Across the Nation 2Health News:The Larry King Cardiac Foundation Brings its Annual Gala to Homes Across the Nation 3Health News:Brain Tumor Drug May Help Spur Cancer's Return 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 3Health News:Medical imaging benefits far outweigh radiation risks 2Health News:AdvaMed Response to the Medical Device Safety Act 2Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 2Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 3Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 4Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 5Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 6Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 7Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 8
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Bipolar forceps...
... the pathologist to visualize the presence of Human ... a choice of sample types: tissue, monolayer-based preparations, ... proprietary probe formulations. The Family 16 probe cocktail ... 31, 33, 35, 39, 51, 52, 56, 58, ...
... Common primary human fungal pathogens ... spp., opportunistic fungal pathogens, including ... cerevisiae, Acremonium, Coccidioides immitis, Histoplasma ... and Pneumocystis carinii. The (1-3)--D-glucan ...
Medicine Products: